Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Long term effect of atropine 0.01% vs atropine 0.05% on higher order aberrations, retinal image quality and contrast sensitivity among children with progressive myopia
Author Affiliations & Notes
  • Vinay Gupta
    Ophthalmology, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Rohit Saxena
    Ophthalmology, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Rebika Dhiman
    Ophthalmology, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Swati Phuljhele
    Ophthalmology, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Namrata Sharma
    Ophthalmology, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Footnotes
    Commercial Relationships   Vinay Gupta None; Rohit Saxena None; Rebika Dhiman None; Swati Phuljhele None; Namrata Sharma None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2840. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vinay Gupta, Rohit Saxena, Rebika Dhiman, Swati Phuljhele, Namrata Sharma; Long term effect of atropine 0.01% vs atropine 0.05% on higher order aberrations, retinal image quality and contrast sensitivity among children with progressive myopia. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2840.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Low-dose atropine [primarily 0.01%(A01) and 0.05%(A05)] reported to affect pupil size, accommodation, optical properties of cornea and lens which can compromise the image quality. The aim of this prospective blinded randomized parallel group study was to evaluate and compare the effect of atropine 0.01% vs 0.05% after 1 year on higher order aberrations(HOAs), retinal image quality and contrast sensitivity at different level of spatial frequencies among progressive myopic children.

Methods : HOAs of 160 children (aged: 6-14yr, refractive error: -1D to -6D) recruited in a parallel-group, blinded, randomized trial [80 each receiving A01 and A05 once at night for 1 year] were measured using itracey wavefront aberrometry at baseline and 1 year follow-up visit. Retinal image quality was assessed using point spread function and represented in terms of Strehl-ratio. Contrast sensitivity over wide range of spatial frequencies (5, 10 & 15 cycles per degree(cpd)) measured objectively through modular transfer function(MTF). Primary analysis was based on intention-to-treat principle.

Results : There was no significant difference noted in age(8.9±2.8yr vs 9.1±2.5yr), myopia(-3.2±1.3 vs -3.5±1.4D) and biometric parameters between A01 vs A05 at baseline (p>0.05 for all). The mean total HOAs were not increased significantly in A01[0.31±0.12µ(baseline) vs 0.34±0.14µ(1 year); p:0.1] and A05[0.3±0.11µ(baseline) vs 0.36±0.16µ(1 year); p:0.07] group after 1 year; but change in HOA was significant between the two groups after 1 year(p:0.046). The A05 shows significant decrease in Strehl-ratio as compared to A01(p: 0.041). The change in MTF was found significant at 10cpd [-0.12±0.05; p:0.03(A01) and -0.14±0.05; p:0.02(A05)] and 15cpd [-0.09±0.04; p:0.042(A01) and -0.12±0.04; p:0.037(A05)] at 1-year follow-up when compared to baseline but not at 5cpd [-0.04±0.02; p:0.06(A01) and -0.04±0.02; p:0.07(A05)].

Conclusions : The effect of atropine on HOAs and retinal image quality is dose dependent. A01 and A05 affects contrast sensitivity at higher spatial frequencies. Objectively, children receiving A05 perceive poorer image quality compared to children receiving A01. Quantifying wavefront aberration and advanced visual function provides, objective assessment of quality of vision of children; and may aids to understand/develop the myopia correction methods.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×